Literature DB >> 7759866

The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation.

D Maurer1, C Ebner, B Reininger, E Fiebiger, D Kraft, J P Kinet, G Stingl.   

Abstract

The discovery that the high affinity IgE receptor (Fc epsilon RI) is expressed on APCs of patients with atopic diseases raised the possibility that the functional importance of Fc epsilon RI in the pathogenesis of atopy may extend beyond its role in type I allergic reactions. Here we show that, following removal of in vivo-bound IgE by lactic acid treatment, targeting of allergens to monocytes by Ag-specific IgE critically depends on Fc epsilon RI expression. Even more importantly, lactic acid-treated, monocyte-enriched PBMCs present allergen to T cells 100- to 1000-fold more effectively if the allergen has been targeted to Fc epsilon RI on these cells via allergen-specific IgE. This mechanism may critically lower the atopic individual's threshold to mount allergen-specific T cell responses capable of promoting IgE production and delayed-type hypersensitivity reactions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7759866

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  63 in total

1.  The high-affinity IgE receptor (FcepsilonRI) blocks apoptosis in normal human monocytes.

Authors:  N Katoh; S Kraft; J H Wessendorf; T Bieber
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

Review 2.  Th1/Th2 balance in atopy.

Authors:  T Biedermann; M Röcken
Journal:  Springer Semin Immunopathol       Date:  1999

3.  Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4+ T cells upon immune-complex uptake in vivo.

Authors:  Judith M H de Jong; Danita H Schuurhuis; Andreea Ioan-Facsinay; Mick M Welling; Marcel G M Camps; Ellen I H van der Voort; Tom W J Huizinga; Ferry Ossendorp; J Sjef Verbeek; René E M Toes
Journal:  Immunology       Date:  2006-09-21       Impact factor: 7.397

4.  IgE-mediated allergen gene vaccine platform targeting human antigen-presenting cells through the high-affinity IgE receptor.

Authors:  Anne Behnecke; Wei Li; Ling Chen; Andrew Saxon; Ke Zhang
Journal:  J Allergy Clin Immunol       Date:  2009-05-07       Impact factor: 10.793

5.  The Clinical Relevance of Various Hypersensitivity Tests in Patients with Atopic Dermatitis as Assessed by Their History, SCORAD Changes, and Number of Days with Need of Anti-Inflammatory Treatment.

Authors:  Martin Liska; Vaclava Gutova; Petr Panzner; Petra Brodska
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2015-06-01       Impact factor: 1.349

6.  IgE signaling suppresses FcepsilonRIbeta expression.

Authors:  Jennifer Brenzovich; Matthew Macey; Josephine Fernando; Hey Jin Chong; Brian Barnstein; Paria Mirmonsef; Johanna K Morales; Akiko Kimura; Tracey Dawson Cruz; John J Ryan
Journal:  J Leukoc Biol       Date:  2009-09-09       Impact factor: 4.962

7.  The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.

Authors:  J Corne; R Djukanovic; L Thomas; J Warner; L Botta; B Grandordy; D Gygax; C Heusser; F Patalano; W Richardson; E Kilchherr; T Staehelin; F Davis; W Gordon; L Sun; R Liou; G Wang; T W Chang; S Holgate
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

8.  Serum IgE clearance is facilitated by human FcεRI internalization.

Authors:  Alexandra M Greer; Nan Wu; Amy L Putnam; Prescott G Woodruff; Paul Wolters; Jean-Pierre Kinet; Jeoung-Sook Shin
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

Review 9.  [Application of humanized Anti-IgE antibodies (omalizumab). A new principle in the treatment of allergic diseases in ENT medicine].

Authors:  O Pfaar; L Klimek
Journal:  HNO       Date:  2007-12       Impact factor: 1.284

Review 10.  [Atopic patch test. Atopic eczema and allergy].

Authors:  U Darsow; J Ring
Journal:  Hautarzt       Date:  2003-10       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.